On January 12, 2026, Juvena Therapeutics, a clinical-stage biotechnology company whose AI-enabled regenerative biologics are designed to restore tissue function, announced its $33.5 million Series B. The financing round was led by Bison Ventures with participation from Eli Lilly and Company, Jefferson Life Sciences, and existing institutional backers including Mubadala Capital and Manta Ray. Wilson Sonsini Goodrich & Rosati advised Juvena on IP matters related to the transaction.

Juvena is conducting Phase 1 clinical studies for its lead asset, JUV-161, a muscle-regenerating biologic shown in preclinical models to enhance myogenesis, improve muscle metabolism and strength, and address muscle degeneration in myopathic conditions. The company will use proceeds the financing round to advance lead clinical programs, expand its pipeline of tissue-restorative biologics, and support continued development of its AI-enabled discovery capabilities.

The Wilson Sonsini team that advised Juvena on IP matters related to the transaction includes Matt Bresnahan, Scott May, Ian Edvalson, and Nguyen Pham.

For more information, please see Juvena's news release.